ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)
- First Posted Date
- 2011-04-13
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 124
- Registration Number
- NCT01334918
- Locations
- 🇺🇸
Cardiovascular Research Center of South Florida, Miami, Florida, United States
🇺🇸Baptist Hospital of Miami, Miami, Florida, United States
🇺🇸Harbor UCLA Medical Center, Torrance, California, United States
Study to Compare the Pharmacokinetics of Tacrolimus in Adult Transplant Recipients Treated With Advagraf® or Prograf®
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2015-06-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 17
- Registration Number
- NCT01332201
A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis
- First Posted Date
- 2011-03-30
- Last Posted Date
- 2016-03-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 83
- Registration Number
- NCT01325571
A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment
- First Posted Date
- 2011-03-21
- Last Posted Date
- 2014-07-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 100
- Registration Number
- NCT01318837
A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication
Withdrawn
- Conditions
- First Posted Date
- 2011-03-17
- Last Posted Date
- 2015-09-02
- Lead Sponsor
- Astellas Pharma Inc
- Registration Number
- NCT01317810
A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal Impairment
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 165
- Registration Number
- NCT01316094
A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 122
- Registration Number
- NCT01316107
A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without Steroids
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-02-28
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1166
- Registration Number
- NCT01304836
A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 67
- Registration Number
- NCT01302041
- Locations
- 🇧🇪
Site BE1002, Kortrijk, Belgium
🇨🇿Site CZ3006, Olomouc, Czechia
🇩🇪Site DE5005, Aachen, Germany
Drug to Drug Interaction Study With ASP1941 and Metformin
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 36
- Registration Number
- NCT01302145
© Copyright 2024. All Rights Reserved by MedPath